Epizyme (NASDAQ:EPZM) Trading 2.6% Higher
Epizyme Inc (NASDAQ:EPZM)’s stock price traded up 2.6% on Monday . The company traded as high as $13.73 and last traded at $14.07, 16,041 shares traded hands during mid-day trading. A decline of 98% from the average session volume of 644,021 shares. The stock had previously closed at $13.72.
A number of equities analysts have recently weighed in on the stock. BidaskClub raised shares of Epizyme from a “hold” rating to a “buy” rating in a research report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $21.00 price target on shares of Epizyme in a research report on Wednesday, June 12th. Zacks Investment Research lowered shares of Epizyme from a “buy” rating to a “hold” rating and set a $15.00 price target for the company. in a research report on Wednesday, August 14th. HC Wainwright set a $25.00 price target on shares of Epizyme and gave the stock a “buy” rating in a research report on Monday, June 24th. Finally, Citigroup reaffirmed a “buy” rating on shares of Epizyme in a research report on Thursday, May 30th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Epizyme has an average rating of “Buy” and an average price target of $18.11.
The company has a debt-to-equity ratio of 0.03, a current ratio of 10.56 and a quick ratio of 10.56. The firm’s 50-day moving average is $12.98 and its 200 day moving average is $12.71. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -7.90 and a beta of 2.48.
In other Epizyme news, CEO Robert B. Bazemore sold 2,074 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $12.10, for a total transaction of $25,095.40. Following the completion of the sale, the chief executive officer now directly owns 87,068 shares in the company, valued at $1,053,522.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David M. Mott sold 104,944 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $13.08, for a total transaction of $1,372,667.52. Following the sale, the director now owns 13,979 shares of the company’s stock, valued at $182,845.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 108,203 shares of company stock valued at $1,412,101. 16.60% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA grew its stake in Epizyme by 7.3% during the first quarter. Primecap Management Co. CA now owns 10,253,801 shares of the biopharmaceutical company’s stock worth $127,045,000 after buying an additional 697,274 shares during the period. Redmile Group LLC boosted its stake in shares of Epizyme by 15.9% in the first quarter. Redmile Group LLC now owns 7,694,020 shares of the biopharmaceutical company’s stock valued at $95,329,000 after purchasing an additional 1,056,742 shares during the period. Vanguard Group Inc. boosted its stake in shares of Epizyme by 29.9% in the second quarter. Vanguard Group Inc. now owns 7,078,470 shares of the biopharmaceutical company’s stock valued at $88,835,000 after purchasing an additional 1,630,171 shares during the period. BlackRock Inc. boosted its stake in shares of Epizyme by 31.8% in the second quarter. BlackRock Inc. now owns 6,440,597 shares of the biopharmaceutical company’s stock valued at $80,831,000 after purchasing an additional 1,552,216 shares during the period. Finally, FMR LLC boosted its stake in shares of Epizyme by 0.3% in the first quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock valued at $43,169,000 after purchasing an additional 11,759 shares during the period. Institutional investors own 83.65% of the company’s stock.
Epizyme Company Profile (NASDAQ:EPZM)
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Featured Story: How to identify percentage decliners
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.